Vertex Pharmaceuticals, Inc.

NASDAQ:VRTX   3:59:59 PM EDT
187.72
-0.13 (-0.07%)
Products

Vertex Announces Primary Endpoint Achieved In Phase 2 Study Of VX-864

Published: 06/10/2021 20:38 GMT
Vertex Pharmaceuticals, Inc. (VRTX) - Vertex Announces Primary Endpoint Achieved in Phase 2 Study of Vx-864 in Alpha-1 Antitrypsin Deficiency.
Vertex Pharmaceuticals Inc - Treatment With Vx-864 Led to Statistically Significant Increase From Baseline in Plasma Functional Aat Levels Versus Placebo.
Vertex Pharmaceuticals Inc - Treatment With Vx-864 Was Generally Well Tolerated.
Vertex Pharmaceuticals Inc - to Advance Additional Novel Small Molecule(s) With Potential for Greater Clinical Efficacy Into Clinic in 2022.
Vertex Pharmaceuticals Inc - Magnitude of Treatment Effect Observed in This Study is Unlikely to Translate Into Substantial Clinical Benefit.
Vertex Pharmaceuticals Inc - Will Not Advance Vx-864 Into Late-stage Development.